An Update on New and Existing Treatments for the Management of Melasma.
Autor: | Gan C; Department of Dermatology, St Vincent's Hospital, Melbourne, VIC, Australia., Rodrigues M; Department of Dermatology, The Royal Children's Hospital, Melbourne, VIC, Australia. michelle.rodrigues@unimelb.edu.au.; Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia. michelle.rodrigues@unimelb.edu.au.; Chroma Dermatology, Pigment and Skin of Colour Centre, Melbourne, VIC, Australia. michelle.rodrigues@unimelb.edu.au. |
---|---|
Jazyk: | angličtina |
Zdroj: | American journal of clinical dermatology [Am J Clin Dermatol] 2024 Sep; Vol. 25 (5), pp. 717-733. Date of Electronic Publication: 2024 Jun 19. |
DOI: | 10.1007/s40257-024-00863-2 |
Abstrakt: | Melasma is a chronic, acquired disorder of focal hypermelanosis that carries significant psychosocial impact and is challenging for both the patient and the treating practitioner to manage in the medium to long term. Multiple treatments have been explored, often in combination given the many aetiological factors involved in its pathogenesis. Therapeutic discoveries to treat melasma are a focal topic in the literature and include a range of modalities, with recent developments including updates on visible light photoprotection, non-hydroquinone depigmenting agents, oral tranexamic acid, chemical peels, and laser and energy-based device therapy for melasma. It is increasingly important yet challenging to remain up-to-date on the arsenal of treatments available for melasma to find an efficacious and well-tolerated option for our patients. (© 2024. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: |